Evidence map›Paper›PMID 40913745›Full record

ArticleCancer immunology, immunotherapy : CII2025

Utility of [

Sarah Boughdad, Sofiya Latifyan, Margret Schottelius, Michael Blue, Stéphanie Tissot, Christine Geldhof, Julien Costes, John O Prior, Niklaus Schaefer

Registry-linked trialAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04663126 (Pilot Study to Test the Feasibility of IV Injected Tc-99m-tilmanocept for Imaging of M2-like Tumour Associated Macrophages in Metastatic Melanoma), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04663126 early_phase1terminatednot on this map

Pilot Study to Test the Feasibility of IV Injected Tc-99m-tilmanocept for Imaging of M2-like Tumour Associated Macrophages in Metastatic Melanoma

TypeinterventionalSponsorJohn O. PriorRan2021 to 2023Enrolled5ConditionsMelanomaArmsTc-99m tilmanocept
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sarah BoughdadDepartment of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, CHUV/UNIL, 1011, Lausanne, Switzerland. Sarah.boughdad@aphp.fr.
Sofiya LatifyanDepartment of Oncology, Lausanne University Hospital, Lausanne, Switzerland.
Margret SchotteliusTranslational Radiopharmaceutical Sciences, CHUV/UNIL, 1011, Lausanne, Switzerland.
Michael BlueNAVIDEA Biopharmaceuticals, Columbus, OH, USA.
Stéphanie TissotDepartment of Oncology, Center of Experimental Therapeutics, Lausanne University Hospital, Lausanne, Switzerland.
Christine GeldhofDepartment of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, CHUV/UNIL, 1011, Lausanne, Switzerland.
Julien CostesDepartment of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, CHUV/UNIL, 1011, Lausanne, Switzerland.
John O PriorDepartment of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, CHUV/UNIL, 1011, Lausanne, Switzerland.
Niklaus SchaeferDepartment of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, CHUV/UNIL, 1011, Lausanne, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmunotherapy is a mainstay in the treatment of patients with advanced melanoma. Yet, resistance mechanisms exist, and tumour-associated macrophages (TAMs), particularly the M2-like phenotype, are associated with poorer outcomes, with CD206 serving as their specific marker. We present the first human SPECT/CT study to visualize CD206 + TAMs in patients undergoing immunotherapy and compare the findings to clinical outcomes (NCT04663126). MATERIAL AND

methodsThis prospective diagnostic open-label, non-randomized, feasibility study aimed to visualize CD206 + cells including M2-like TAM in target lesions (T-Lesion) of melanoma patients treated with immunotherapy using [

resultsFive patients were recruited. T-Lesion uptake on [

conclusionThese preliminary pilot data provide the first-in-human proof of concept that CD206-based functional imaging showed measurable signal in tumour lesions in patients with advanced melanoma. If validated it might be useful in reflecting tumour immune status, hence help predicting tumour response to ICI.

Indexed as

Immune Checkpoint InhibitorsMacrophagesMelanomaRadiopharmaceuticalsSingle Photon Emission Computed Tomography Computed TomographyTechnetium Tc 99m PentetateTumor-Associated MacrophagesAdultAgedDextransFeasibility StudiesFemaleHumansMaleMannansMiddle AgedDextransImmune Checkpoint InhibitorsMannansRadiopharmaceuticalstechnetium-diethylenetriaminepentaacetic acid-mannosyl-dextranTechnetium Tc 99m Pentetate[99mTc]Tc-TilmanoceptCD206 imagingImmune checkpoint inhibitorsPrediction of responseQuantitative SPECT/CT

Identifiers

PMID40913745
PMCPMC12414091

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.